Tartaglia, M. & Gelb, B.D. Noonan syndrome and related disorders: genetics and pathogenesis. Annu. Rev. Genomics Hum. Genet. 6, 45–68 (2005).
Romano, A.A. et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 126, 746–759 (2010).
Lee, D.A., Portnoy, S., Hill, P., Gillberg, C. & Patton, M.A. Psychological profile of children with Noonan syndrome. Dev. Med. Child Neurol. 47, 35–38 (2005).
van der Burgt, I. et al. Patterns of cognitive functioning in school-aged children with Noonan syndrome associated with variability in phenotypic expression. J. Pediatr. 135, 707–713 (1999).
Cesarini, L. et al. Cognitive profile of disorders associated with dysregulation of the RAS/MAPK signaling cascade. Am. J. Med. Genet. A. 149A, 140–146 (2009).
Pierpont, E.I. et al. Genotype differences in cognitive functioning in Noonan syndrome. Genes Brain Behav. 8, 275–282 (2009).
Verhoeven, W., Wingbermuhle, E., Egger, J., Van der Burgt, I. & Tuinier, S. Noonan syndrome: psychological and psychiatric aspects. Am. J. Med. Genet. A. 146A, 191–196 (2008).
Alfieri, P. et al. Long term memory profile of disorders associated with dysregulation of the RAS-MAPK signaling cascade. Behav. Genet. 41, 423–429 (2011).
Pierpont, E.I., Tworog-Dube, E. & Roberts, A.E. Learning and memory in children with Noonan syndrome. Am. J. Med. Genet. A 161, 2250–2257 (2013).
Zenker, M. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors. Curr. Opin. Pediatr. 23, 443–451 (2011).
Neel, B.G., Gu, H. & Pao, L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28, 284–293 (2003).
Sweatt, J.D. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J. Neurochem. 76, 1–10 (2001).
Fragale, A., Tartaglia, M., Wu, J. & Gelb, B.D. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum. Mutat. 23, 267–277 (2004).
Araki, T. et al. Mouse model of Noonan syndrome reveals cell type– and gene dosage–dependent effects of Ptpn11 mutation. Nat. Med. 10, 849–857 (2004).
Keilhack, H., David, F.S., McGregor, M., Cantley, L.C. & Neel, B.G. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J. Biol. Chem. 280, 30984–30993 (2005).
Araki, T. et al. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc. Natl. Acad. Sci. USA 106, 4736–4741 (2009).
Morris, R.G., Garrud, P., Rawlins, J.N. & O'Keefe, J. Place navigation impaired in rats with hippocampal lesions. Nature 297, 681–683 (1982).
Tartaglia, M. et al. Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease. Am. J. Hum. Genet. 78, 279–290 (2006).
Lee, Y.S. & Silva, A.J. The molecular and cellular biology of enhanced cognition. Nat. Rev. Neurosci. 10, 126–140 (2009).
Gauthier, A.S. et al. Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome. Neuron 54, 245–262 (2007).
Zhu, J.J., Qin, Y., Zhao, M., Van Aelst, L. & Malinow, R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell 110, 443–455 (2002).
Li, W. et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr. Biol. 15, 1961–1967 (2005).
Sebti, S.M., Tkalcevic, G.T. & Jani, J.P. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun. 3, 141–147 (1991).
Mailman, T., Hariharan, M. & Karten, B. Inhibition of neuronal cholesterol biosynthesis with lovastatin leads to impaired synaptic vesicle release even in the presence of lipoproteins or geranylgeraniol. J. Neurochem. 119, 1002–1015 (2011).
Lee, S.H. et al. Synapses are regulated by the cytoplasmic tyrosine kinase Fer in a pathway mediated by p120catenin, Fer, SHP-2, and β-catenin. J. Cell Biol. 183, 893–908 (2008).
Pagani, M.R., Oishi, K., Gelb, B.D. & Zhong, Y. The phosphatase SHP2 regulates the spacing effect for long-term memory induction. Cell 139, 186–198 (2009).
Rumbaugh, G., Adams, J.P., Kim, J.H. & Huganir, R.L. SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons. Proc. Natl. Acad. Sci. USA 103, 4344–4351 (2006).
Stornetta, R.L. & Zhu, J.J. Ras and Rap signaling in synaptic plasticity and mental disorders. Neuroscientist 17, 54–78 (2011).
Tidyman, W.E. & Rauen, K.A. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr. Opin. Genet. Dev. 19, 230–236 (2009).
Shilyansky, C., Lee, Y.S. & Silva, A.J. Molecular and cellular mechanisms of learning disabilities: a focus on NF1. Annu. Rev. Neurosci. 33, 221–243 (2010).
Shilyansky, C. et al. Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc. Natl. Acad. Sci. USA 107, 13141–13146 (2010).
Cui, Y. et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 135, 549–560 (2008).
Costa, R.M. et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415, 526–530 (2002).
Zolotukhin, S. et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28, 158–167 (2002).
Hajos, N., Nusser, Z., Rancz, E.A., Freund, T.F. & Mody, I. Cell type- and synapse-specific variability in synaptic GABAA receptor occupancy. Eur. J. Neurosci. 12, 810–818 (2000).